Humacyte Advances in Vascular Repair with Innovative Bioengineered Tissues. Humacyte (NASDAQ:HUMA) is developing universally implantable, bioengineered human tissues.Their lead product candidates ...

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to ...

The U.S. Food and Drug Administration (FDA) granted a full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s HUMA Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

Humacyte (NASDAQ:HUMA) shares climbed ~57% in the premarket on Friday after the bioengineered tissue maker announced the FDA approval of Symvess, an off-the-shelf, implantable vascular conduit ...

The FDA approved Symvess as a vascular conduit for extremity arterial injuries in adults when urgent revascularization is needed to avoid limb loss, and an autologous vein graft is not feasible ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury ...

The implantable vascular conduit, which is indicated for arterial injury, won FDA approval in December 2024. Symvess is intended for use in both hospitals and for military use. Although repairing ...

Mar 4, 2025, 5:43am PST Updated: Mar 4, 2025, 6:22am PST Mehmet Demirci Dr. Laura Niklason, CEO of Humacyte STORY HIGHLIGHTS FDA approves Humacyte's Symvess for vascular trauma treatment. Symvess ...

The approval was based on data from the prospective, single-arm, multicenter phase 2/3 V005 study (ClinicalTrials.gov Identifier: NCT03005418), which evaluated Symvess in adults with life- or limb ...